

ICPO THERANOSTICS VIRTUAL SUMMIT 2024

New Era of Alpha Emitters and Radiopharmaceuticals



Preliminary Program (Version July 23, 2024)

Day 1, November 14, 2024

Alpha Emitters with focus on Ac225, At211 and Pb212 // Latest innovation and clinical establishment today // Patient access and global perspective.

2:00 pm - 2:20 pm	Welcome
2:20 pm - 2:40 pm	Keynote: History of Alpha Therapy S. Larson (USA)
2:40 pm - 3:25 pm	SESSION I: Alpha Emitters 101 <ul style="list-style-type: none">• Radiobiology need to know about Alphas - J-P. Pouget (France)• Dosimetry techniques for alpha radioligand therapy: where are we now? - P. Fragoso Costa (Germany)• Radiochemistry Alpha specificities and latest advances - M. Nader (Germany)
3:25 pm - 4:25 pm	SESSION II: Alpha Emitters from Bench to Bed Side <ul style="list-style-type: none">• Ac225 Clinical Insights from WARMTH Act LANCET Oncology Study - M. Sathekge (South Africa)• At211 from preclinical to the clinic - T. Watabe (Japan)• Pb212 Preclinical Experience and Clinical Potential - N. Pullen (Switzerland)• Pb212 PSMA Clinical experience in prostate cancer and isotope considerations for novel targets, binders and indications" A. Karmann (USA)
4:25 pm - 4:35 pm	BREAK
4:35 pm - 5:20 pm	SESSION III : Alpha Emitters beyond PSMA <ul style="list-style-type: none">• Innovation in Ac225 Supply - C.S. Cutler (USA)• Next-generation SSTR2 targeting in Small Cell Lung Cancer with Ac-225 -G. Gericke (Germany)• Pb212 Dotamate in NET - E. Delpassand (USA)
5:20 pm - 6:35 pm	SESSION IV: Challenges of Alpha therapies versus conventional emitters <ul style="list-style-type: none">• Global supply status and challenges of Ac225 and other alphas - Neil Quigley (Germany)• At211 the European Network - J-F Gestin (France)• Pb212 Generators: Different Concepts & Logistics - M. Schultz (USA)• Regulatory Perspective on the Introduction on Alpha Therapies - TBC• Ethics in Clinical trials on Alpha Therapies - J. Mailman (USA)
6:35 pm - 7:20 pm	PANEL 1: Global perspective on patient access today and in 5 years Moderators: R.P. Baum and F. Giesel (Germany)
7:20 pm - 7:30 pm	Wrap up and Closing of Day 1

ICPO THERANOSTICS VIRTUAL SUMMIT 2024

New Era of Alpha Emitters and Radiopharmaceuticals



Preliminary Program (Version July 23, 2024)

Day 2, November 15, 2024

Radiopharmaceuticals with focus on FAP, CA9, CXCR4 and GPC3 // From trials to clinical profiles // Patient access and global perspective

9:00 am - 9:10 am	Welcome
9:10 am - 9:30 am	Keynote: History of FAP till today A. Scott (Australia)
9:30 am - 10:45 am	SESSION V: FAP Diagnostics in Oncology and non-Oncology <ul style="list-style-type: none">FAP Dx into clinical practice today – malignant and non-malignant - F. Giesel (Germany)Myocardial and Organ Fibrosis - TBCFAP Dx Some On-going Clinical Trials - S. Mosessian (USA)
10:45 am - 11:30 am	SESSION VI: FAP Therapy <ul style="list-style-type: none">FAP Peptide Targeted Tx - R.P. Baum (Germany)FAP Dimer - S. Ballal (India)Optimisation of FAP ligands for therapy through multimerization and medicinal chemistry approaches - J. Mock (Switzerland)
11:30 am - 10:50 am	PANEL 2: FAP as Imaging Biomarker Moderator: E. Zan (USA)
11:50 am - 12:00 am	BREAK
12:00 am - 12:45 am	SESSION VII: CA9 <ul style="list-style-type: none">G250 Antibody Renal Cell Cancer - S.T. Lee (Australia)CA9 Theranostics with Small Molecules - M. Hofman (Australia)CA9 Some On-going Clinical Trials - D. Cade and S. Gribble (Australia)
12:45 am - 1:45 pm	SESSION VIII: CXCR4 and GPC3 <ul style="list-style-type: none">CXCR4 Hematological Indications - R. Werner (Germany)CXCR4 some On-going Clinical Trials - H. Bouterfa (Germany)GPC3 Promise for Oncology - W. Weber (Germany)GPC1 Promise for Oncology - S. Serada (Japan)
1:45 pm - 2:05 pm	PANEL 3: Antibody Drug Conjugates contra Radiopharmaceutical Therapies? Moderator: K. Herrmann (Germany)
2:05 pm - 2:50 pm	FINAL ROUND TABLE: A new theranostics era for patients, fueled by innovation & regulatory advances
2:50 pm - 3:00 pm	Wrap up and Closing of Summit 2024